redness spread and it felt warm to the touch; redness spread and it felt warm to the touch; itching and turning red; soreness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (soreness), INJECTION SITE WARMTH (redness spread and it felt warm to the touch), INJECTION SITE PRURITUS (itching and turning red) and INJECTION SITE ERYTHEMA (redness spread and it felt warm to the touch) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced PAIN IN EXTREMITY (soreness). On 20-Jan-2021, the patient experienced INJECTION SITE PRURITUS (itching and turning red). On 21-Jan-2021, the patient experienced INJECTION SITE WARMTH (redness spread and it felt warm to the touch) and INJECTION SITE ERYTHEMA (redness spread and it felt warm to the touch). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (soreness), INJECTION SITE WARMTH (redness spread and it felt warm to the touch), INJECTION SITE PRURITUS (itching and turning red) and INJECTION SITE ERYTHEMA (redness spread and it felt warm to the touch) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 21-Jan-2021 and was forwarded to Moderna on 22-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (soreness), INJECTION SITE WARMTH (redness spread and it felt warm to the touch), INJECTION SITE PRURITUS (itching and turning red) and INJECTION SITE ERYTHEMA (redness spread and it felt warm to the touch) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.     On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced PAIN IN EXTREMITY (soreness). On 20-Jan-2021, the patient experienced INJECTION SITE PRURITUS (itching and turning red). On 21-Jan-2021, the patient experienced INJECTION SITE WARMTH (redness spread and it felt warm to the touch) and INJECTION SITE ERYTHEMA (redness spread and it felt warm to the touch). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (soreness), INJECTION SITE WARMTH (redness spread and it felt warm to the touch), INJECTION SITE PRURITUS (itching and turning red) and INJECTION SITE ERYTHEMA (redness spread and it felt warm to the touch) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided.  No treatment details were reported.